Updates from Bausch and Lomb: US launch of FDA approved treatment for uveitis, new IOL toric calculator

Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.

Related Content:

ASCRSVideosConferencesTherapeuticsClinicalExpert Interviews
Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Technology, people key to improving health outcomes, driving revenue